Your browser is no longer supported. Please, upgrade your browser.
Settings
PRVB [NASD]
Provention Bio, Inc.
Index- P/E- EPS (ttm)-2.10 Insider Own19.02% Shs Outstand62.26M Perf Week-0.65%
Market Cap382.77M Forward P/E- EPS next Y-1.72 Insider Trans0.00% Shs Float47.69M Perf Month-28.00%
Income-118.40M PEG- EPS next Q-0.52 Inst Own47.70% Short Float10.90% Perf Quarter-17.97%
Sales- P/S- EPS this Y-76.90% Inst Trans18.46% Short Ratio1.93 Perf Half Y-57.55%
Book/sh2.95 P/B2.06 EPS next Y19.20% ROA-70.70% Target Price- Perf Year-41.30%
Cash/sh3.29 P/C1.85 EPS next 5Y- ROE-79.70% 52W Range5.59 - 20.05 Perf YTD-64.17%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-68.75% Beta-
Dividend %- Quick Ratio7.90 Sales past 5Y- Gross Margin- 52W Low12.08% ATR0.46
Employees59 Current Ratio7.90 Sales Q/Q- Oper. Margin- RSI (14)42.42 Volatility4.68% 6.89%
OptionableYes Debt/Eq0.00 EPS Q/Q-97.50% Profit Margin- Rel Volume0.14 Prev Close6.07
ShortableYes LT Debt/Eq0.00 EarningsAug 05 BMO Payout- Avg Volume2.69M Price6.26
Recom2.00 SMA20-1.56% SMA50-16.43% SMA200-46.43% Volume246,937 Change3.21%
Apr-09-21Reiterated SVB Leerink Outperform $26 → $16
Apr-09-21Downgrade RBC Capital Mkts Outperform → Sector Perform $27 → $25
Jun-16-20Reiterated H.C. Wainwright Buy $20 → $26
Jun-04-20Initiated RBC Capital Mkts Outperform $25
Jun-04-20Initiated Oppenheimer Outperform $29
Jan-24-20Initiated Cantor Fitzgerald Overweight $25
Jun-26-19Reiterated H.C. Wainwright Buy $8 → $20
Jun-10-19Initiated Chardan Capital Markets Buy $20
Feb-22-19Initiated SVB Leerink Outperform $6
Jul-29-21 07:00AM  
Jul-20-21 02:20PM  
01:35PM  
10:40AM  
10:03AM  
09:36AM  
Jul-19-21 03:51PM  
03:00PM  
02:30PM  
12:21PM  
10:40AM  
10:15AM  
10:00AM  
10:00AM  
09:00AM  
05:40AM  
12:50AM  
Jul-18-21 11:49AM  
09:30AM  
09:00AM  
Jul-16-21 07:30PM  
03:53PM  
02:10PM  
01:05PM  
11:35AM  
11:25AM  
10:35AM  
10:11AM  
06:52AM  
Jul-15-21 07:37PM  
06:05PM  
04:01PM  
02:30PM  
12:30PM  
12:00PM  
11:00AM  
10:30AM  
10:03AM  
05:40AM  
12:50AM  
Jul-14-21 09:00PM  
06:34PM  
05:09PM  
02:30PM  
01:00PM  
09:30AM  
09:00AM  
05:40AM  
01:30AM  
Jul-13-21 08:15PM  
07:45PM  
01:40PM  
01:00PM  
11:45AM  
11:00AM  
05:40AM  
12:20AM  
Jul-12-21 06:54PM  
04:51PM  
01:00PM  
01:00PM  
11:30AM  
08:48AM  
07:00AM  
05:40AM  
Jul-11-21 11:55PM  
10:30AM  
Jul-10-21 06:46AM  
Jul-09-21 06:23PM  
04:59PM  
04:51PM  
03:33PM  
02:00PM  
Jul-08-21 12:00PM  
11:00AM  
10:00AM  
05:30AM  
Jul-07-21 11:00PM  
09:10PM  
08:22PM  
03:58PM  
02:30PM  
12:58PM  
11:30AM  
11:15AM  
10:10AM  
Jul-06-21 04:49PM  
04:30PM  
03:21PM  
03:21PM  
01:35PM  
01:00PM  
11:45AM  
11:00AM  
10:45AM  
09:53AM  
07:55AM  
07:00AM  
Jul-05-21 11:10PM  
11:00PM  
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which has completed Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. The company was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Drechsler Andrew TChief Financial OfficerSep 02Buy11.722,00023,44020,000Sep 02 05:00 PM
Ramos EleanorChief Medical OfficerSep 02Buy12.062993,60664,799Sep 02 07:43 PM
Leon FranciscoChief Scientific OfficerAug 21Buy13.352,00026,7082,567,450Aug 21 04:05 PM
Ramos EleanorChief Medical OfficerAug 20Buy13.232,50033,07564,500Aug 20 06:52 PM
Palmer AshleighPresident and CEOAug 18Buy12.695006,3452,566,300Aug 18 06:10 PM
Palmer AshleighPresident and CEOAug 17Buy12.832,80035,9242,565,800Aug 17 07:20 PM
Drechsler Andrew TChief Financial OfficerAug 13Buy13.011,75022,76818,000Aug 13 07:01 PM